Skip to main content
. 2022 Feb 28;42(1):63–74. doi: 10.14639/0392-100X-N1561

Table III.

Univariate and multivariable Cox’s proportional hazard models for the analyzed background variables supported for the need for revision ESS. Only the CRS subjects who underwent ESS at the baseline (n = 48) were included. Bold values denote statistical significance at the p < 0.05 level. The second model is a multivariable model adjusted by the variables that were associated with the need for revision ESS at p < 0.05 level in the first model.

N All N (%) Events HR (95% CI) p aHR (95% CI) p
Gender Female 30 5 (16.7) 2.29 (0.70-7.52) 0.17 Not entered
Male 18 6 (33.3)
Age 1.009 (0.97-1.05) 0.66 Not entered
CRSwNP No 31 7 (22.6) 1.06 (0.31-3.63) 0.93 Not entered
Yes 16 4 (25.0)
Asthma and/or NERD No 30 7 (23.3) 0.82 (0.21-3.18) 0.78 Not entered
Yes 15 3 (20.0)
AR No 21 6 (28.6) 0.54 (0.15-1.91) 0.34 Not entered
Yes 24 4 (16.7)
≥ 1 OCS courses/year No 41 7 (17.1) 3.90 (1.14-13.4) .031 3.14 (0.88-11.2) .079
Yes 7 4 (57.1)
Previous ESS No 34 5 (14.7) 3.57 (1.09-11.71) .036 2.21 (0.45-10.9) .33
Yes 13 6 (46.2)
LM score 1.04 (0.92–1.17) .53 Not entered
Radiological score 1.93 (1.07-3.50) .029 1.41 (0.65-3.07) .39

aHR: adjusted Hazard Ratio; AR: allergic rhinitis; CI: confidence interval; CRS: chronic rhinosinusitis; CRSwNP: chronic rhinosinusitis with nasal polyps; ESS: endoscopis sinus surgery; HR: Hazard Ratio; LM: Lund-Mackay; NERD: NSAIDs exacerbated respiratory disease; NSAIDs: non-steroidal anti-inflammatory drugs; OCS:oral corticosteroid(s). Data was missing in many variations.